Protective Effect of Sevoflurane vs Propofol in HVR Surgery Protective Effect of Sevoflurane vs Propofol in HVR Surgery

This study compared the cardioprotective effect of anesthesia with intravenous propofol versus inhaled sevoflurane in patients undergoing mitral, aortic or tricuspid valve replacement surgery.BMC Anesthesiology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Related Links:

RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefit...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
Cardiovalve announced that it received FDA Breakthrough Device Designation for its Transcatheter Tricuspid Valve Replacement System. The company also received approval for an Early Feasibility Study of the device for tricuspid and mitral valve r...
Source: Medgadget - Category: Medical Devices Authors: Tags: Anesthesiology Cardiac Surgery Cardiology Radiology Source Type: blogs
We report an incidence of right atrial puncture using a percutaneous coronary sinus catheter (CSC) (EndoPlege; Edwards Lifesciences, Irvine, CA) during a planned aortic valve replacement and aortic root plasty via mini-thoracotomy. A 70-year-old woman with severe aortic stenosis, bicuspid aortic valve, and aortic root dilation presented for minimally invasive aortic valve replacement and aortic root repair. After induction and establishing central venous access, the CSC was advanced by the anesthesiologist through the 14-Fr introducer into the coronary sinus under a combination of transesophageal echocardiogram (TEE) and f...
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Letter to the Editor Source Type: research
TRANSCATHETER AORTIC valve replacement (TAVR) has revolutionized the treatment of aortic stenosis (AS). Surgical intervention to treat AS (before TAVR) mandated general anesthesia, invasive vascular monitoring, sternotomy, cardiopulmonary bypass, and several days of postoperative hospital stay. With balloon aortic valvuloplasty being the only palliative percutaneous option, surgery was the only interventional treatment for AS as recent as 15 years ago. Initial approval for TAVR use began with Comite Europee Marking in 2007 and United States Food and Drug Administration (FDA) approval in 2011, and the procedure has been rap...
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Expert Review Source Type: research
GERBODE DEFECT, a communication from the left ventricle (LV) to right atrium (RA), can be congenital or acquired.1,2 The congenital form involves the membranous portion of the interventricular septum extending to the atrial aspect. A defect communicating from the LV to the RA above the septal leaflet of the tricuspid valve is characteristic of the acquired form.3 Previous heart valve surgery, infective endocarditis, and myocardial infarct have been reported to be potential causes of the acquired form.
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Case Report Source Type: research
OVER THE years, the prognostic value of right ventricular (RV) function in cardiac surgery increasingly has been recognized. RV dysfunction is associated with morbidity and mortality both in patient populations with well-known risk factors for RV dysfunction and in more general cardiac surgery populations.1-5
Source: Journal of Cardiothoracic and Vascular Anesthesia - Category: Anesthesiology Authors: Tags: Original Article Source Type: research
Publication date: Available online 14 February 2020Source: Anaesthesia Critical Care &Pain MedicineAuthor(s): Emmanuel Rineau, Chloé Lieppe, Laurence Chausseret, Sophie Provenchere, Philippe Mauriat
Source: Anaesthesia, Critical Care and Pain Medicine - Category: Anesthesiology Source Type: research
Abbott just announced that it is the first company to receive European regulatory approval to introduce transcatheter mitral valve replacement procedures on the continent. The Tendyne Transcatheter Mitral Valve Implantation (TMVI) system is intended ...
Source: Medgadget - Category: Medical Devices Authors: Tags: Anesthesiology Cardiac Surgery Cardiology Radiology Source Type: blogs
This study aimed to assess the perioperative outcomes of adjunctive hypnotherapy undergoing transfemoral TAVI with LACS.Consecutive patients (n = 143) with symptomatic severe aortic stenosis who underwent transfemoral TAVI with LACS only (n = 107) or with LACS and hypnotherapy (n = 36) between January 2015 and April 2016 were retrospectively included in the study. The clinical outcomes were compared between the two groups. The LACS with hypnotherapy group had a significantly shorter length of stay in the intensive care unit (ICU; LACS only versus LACS with hypnotherapy: 4.0 (4.0-5.5) days versus 3.0 (3.0-5.0) days, P
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
More News: Anesthesia | Anesthesiology | Cardiology | Diprivan | Health | Heart | Heart Valve Surgery | Propofol | Sevoflurane | Study | Ultane